Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
triple-negative breast cancer
Biotech
BMS' ADC hits primary endpoints in phase 3 breast cancer trial
The Chinese trial hit its dual primary survival endpoints, providing further validation of the Big Pharma's $800 million bet on the candidate.
Nick Paul Taylor
Feb 26, 2026 9:08am
Mersana lays off 55% of staff, narrows focus to B7-H4 ADC
May 6, 2025 9:40am
BioNTech posts overall survival data on would-be Keytruda killer
Dec 10, 2024 9:00am
Death drives Lyell to take 2-track approach to dose escalation
Jun 26, 2024 10:00am
Gilead draws up $20M pact with cancer biotech Cartography
May 28, 2024 10:26am
Puma pounces on failed Takeda drug, snapping up cancer prospect
Sep 21, 2022 9:05am
